Active Pharmaceutical Ingredient Diabetes Drug For Weight Loss CAS Number CAS 2023788-19-2

is an advanced pharmaceutical compound developed by Eli Lilly and Company. It is classified as a dual agonist for the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual action makes effective in managing type 2 diabetes and has shown significant promise in promoting weight loss. Marketed under the brand name , has garnered attention for its efficacy and innovative mechanism of action.

Peptide Powder Explained peptide powder refers to the raw, unprocessed form of the molecule. As a peptide, it consists of a specific sequence of amino acids that enable it to interact with the GIP and GLP-1 receptors in the body. The powder form is typically intended for research purposes, pharmaceutical manufacturing, or compounding into injectable solutions under controlled conditions.

1. Enhances Insulin Secretion: By activating both GIP and GLP-1 receptors, increases insulin production in response to elevated blood glucose levels, helping to maintain better glucose control in individuals with diabetes.
2. Suppresses Glucagon Release: reduces the release of glucagon, the hormone responsible for increasing blood sugar, which contributes to more stable blood glucose levels.
3. Facilitates Weight Loss: It slows gastric emptying and reduces appetite, leading to lower calorie intake and significant weight loss, making it highly effective for weight management in both diabetic and non-diabetic patients.
4. Improves Insulin Sensitivity: enhances the body's responsiveness to insulin, reducing insulin resistance, a key issue in type 2 diabetes.